Belimumab to help highly sensitized kidney transplant candidates
Part of Immune system & allergy, Kidney & urinary clinical trials.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Be a candidate for kidney transplantation
- Be highly sensitized, meaning very few donor organs would match you
- Not be pregnant or breastfeeding, or agree to use effective contraception during the study
- Not have received certain immune-suppressing medications in the past year
- Not have active infections or serious immune system problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether belatacept can help prevent damage in kidney transplant recipients who develop new antibodies against their donor kidney. It is for people whose kidney function is still stable, which may allow treatment to slow or stop antibody-related injury.
This early-phase trial tests a new therapy that uses your own immune cells to reduce your body's attack on a new kidney. It aims to help people who are highly sensitized (hard to match) get a transplant successfully.
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
This trial tests a new drug called a BiTE (a type of immunotherapy) to lower very high antibody levels in people waiting for a kidney transplant. If successful, it might help you become eligible for a transplant sooner.
This trial tests an experimental drug called om336 to lower antibodies that make it hard to receive a kidney transplant. It aims to help people who have been waiting a long time for a kidney due to high antibody levels.
This study tests a new treatment called BiTE (a type of immunotherapy that helps your immune cells attack harmful antibodies) for people whose transplanted kidney is being damaged by chronic active antibody-mediated rejection. The goal is to see if it can safely slow or stop this damage.
Hear when a new Kidney Transplant Rejection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.